Introduction
The risks of systemic ototoxicity from various drugs, such as the aminoglycosides, are well known. Less well known is the potential for ototoxicity when these drugs are prescribed as ear drops for patients with tympanic membrane perforations. Although some antibiotic ear drops have been used for 40 years in Australia, ototoxicity has become an increasing concern globally over the last ten years. Aminoglycoside ototoxicity can affect not only the cochlea (hearing) but also the vestibular (balance) system.
Aminoglycoside ototoxicity
The most frequently prescribed antibiotic ear drops in Australia are a combination of framycetin (an aminoglycoside), gramicidin and dexamethasone. Aminoglycoside ear drops may cause hearing loss or balance disorder in about 1 in 10 000 patients, but the true incidence of topical ototoxicity is unknown.
It may be much more common, but not recognised for various reasons, including:
n lack of pre-and post-treatment audiograms or balance assessment n lack of audiologic testing for frequencies greater than 8000 Hz n attribution of any hearing loss to the underlying disease process.
There is no doubt that some ingredients of older ear drops, 
Conclusion
The ototoxicity of commonly prescribed aminoglycoside ear drops, although rare, poses a therapeutic dilemma for the prescribing physician. The use of ototoxic ear drops should be avoided in patients with perforations of the tympanic membrane. The Australian recommendations provide a clear plan of management for the discharging middle ear and raise awareness of an alternative therapeutic option using non-ototoxic fluoroquinolone rather than potentially ototoxic ear drops.
